CARM

Carisma Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website carismatx.com
Employees(FY) -
ISIN US14216R1014

Performance

-13.84%

-51.8%

-57.38%

-59.43%

-85.74%

YTD

-85.39%

Profile

Carisma Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Advanced Technical Analysis

Technical Analysis of CARM 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score at 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CARM

Stock Rank

Recent News & Updates

2024-12-08 19:30
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline(Prnewswire)
2024-11-26 18:30
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference(Prnewswire)
2024-11-16 18:30
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting 2024(Prnewswire)
2024-11-07 18:30
Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma(Prnewswire)
2024-11-06 18:30
Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Prnewswire)
2024-11-04 20:05
Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024(Prnewswire)
2024-10-30 04:30
Carisma Therapeutics Announces Changes to its Board of Directors(Prnewswire)
2024-10-03 21:05
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024(Prnewswire)
2024-09-09 19:30
Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune Diseases(Prnewswire)
2024-09-02 19:30
Carisma Therapeutics to Present at Upcoming Conferences(Prnewswire)
2024-08-13 00:00
CARISMA THERAP (CARM) Upgraded to Buy: What Does It Mean for the Stock?(Yahoo Finance)
2024-08-07 21:00
Carisma Therapeutics Inc. (CARM) Reports Q2 Loss, Tops Revenue Estimates(Yahoo Finance)
2024-08-07 19:30
Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights(Prnewswire)
2024-08-05 19:30
Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board(Prnewswire)
2024-08-05 19:30
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024(Prnewswire)
2024-06-30 19:30
Carisma Therapeutics Announces Changes to its Board of Directors(Prnewswire)
2024-06-27 19:39
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday(Investorplace)
2024-06-27 04:30
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna(Prnewswire)
2024-06-25 18:53
Carisma Therapeutics solid tumour therapy obtains FDA Fast Track status(Yahoo Finance)
2024-06-24 19:30
Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum(Prnewswire)
2024-06-24 19:30
Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors(Prnewswire)
2024-06-13 04:30
Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders(Prnewswire)
2024-05-29 19:30
Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference(Prnewswire)
2024-05-15 19:30
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte(Prnewswire)
2024-05-09 01:54
CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024(Investorplace)
2024-05-08 20:35
Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates(Zacks)
2024-05-08 19:30
Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights(Prnewswire)
2024-05-07 19:30
Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024(Prnewswire)
2024-05-05 19:30
Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference(Prnewswire)
2024-05-01 22:01
Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release(Zacks)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.